Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • PharmAbcine, 3SBio deal

    PharmAbcine Inc., Daejon, South Korea 3SBio Inc., Shenyang, China Business: Cancer PharmAbcine granted 3SBio an exclusive license to develop, manufacture and market DIG-KT in Taiwan, Korea and China, including Macau and…

    Published on 1/19/2015
  • Regado Biosciences, Tobira deal

    Regado Biosciences Inc. (NASDAQ:RGDO), Basking Ridge, N.J. Tobira Therapeutics Inc., San Francisco, Calif. Business: Hepatic Tobira will acquire Regado through a reverse merger in a deal slated to close next quarter. …

    Published on 1/19/2015
  • The George Washington University, La Jolla Pharmaceutical deal

    The George Washington University, Washington, D.C. La Jolla Pharmaceutical Co. (NASDAQ:LJPC), San Diego, Calif. Business: Cardiovascular La Jolla received exclusive, worldwide rights to the universitys patents covering …

    Published on 1/19/2015
  • Trophos, Roche deal

    Trophos S.A., Marseille, France Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Autoimmune, Neurology, Cardiovascular Roche will acquire Trophos for 120 million ($142 million) up front and up to 350 million ($…

    Published on 1/19/2015
  • University of Texas MD Anderson Cancer Center, Intrexon, Ziopharm Oncology deal

    University of Texas MD Anderson Cancer Center, Houston, Texas Intrexon Corp. (NYSE:XON), Germantown, Md. Ziopharm Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Business: Cancer Intrexon and Ziopharm received an exclusive …

    Published on 1/19/2015
  • Vedanta, J&J deal

    Vedanta Biosciences Inc., Boston, Mass. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Vedanta granted Johnson & Johnsons Janssen Biotech Inc. exclusive, worldwide rights to VE-202. Janssen will …

    Published on 1/19/2015
  • 23andMe, Roche deal

    23andMe Inc., Mountain View, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Neurology 23andMe partnered with Roches Genentech Inc. unit to identify drug targets for Parkinsons disease (PD) using …

    Published on 1/12/2015
  • Acura, Egalet deal

    Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Business: Neurology Acura granted Egalet exclusive, worldwide rights to commercialize Oxaydo oxycodone tablets formulated …

    Published on 1/12/2015
  • Affibody, Nordic Nanovector deal

    Affibody AB, Stockholm, Sweden Nordic Nanovector A/S, Oslo, Norway Business: Cancer The companies partnered to discover and develop radioimmunotherapies to treat multiple myeloma. Under the three-year deal, the partners…

    Published on 1/12/2015
  • Agenus, Incyte deal

    Agenus Inc. (NASDAQ:AGEN), Lexington, Mass. Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Business: Antibodies Agenus granted Incyte exclusive, worldwide rights to develop and commercialize hematology and oncology immuno…

    Published on 1/12/2015
  • Anaptys, Tesaro deal

    AnaptysBio Inc., San Diego, Calif. Tesaro Inc. (NASDAQ:TSRO), Waltham, Mass. Business: Cancer The companies added a bispecific antibody against two undisclosed immune checkpoint receptors to a 2014 deal granting Tesaro …

    Published on 1/12/2015
  • California Institute for Biomedical Research, Bristol-Myers deal

    California Institute for Biomedical Research, La Jolla, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Pharmaceuticals The institute granted the pharma an exclusive, worldwide license to develop, …

    Published on 1/12/2015
  • Caribou Biosciences, Novartis deal

    Caribou Biosciences Inc., Berkeley, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Gene/Cell therapy Caribou granted Novartis a non-exclusive, worldwide option to license the biotechs CRISPR-Cas9 …

    Published on 1/12/2015
  • Cytos, OnCore Biopharma deal

    Cytos Biotechnology AG (SIX:CYTN), Schlieren, Switzerland OnCore Biopharma Inc., Doylestown, Pa. Business: Infectious OnCore received exclusive, worldwide rights to use Cytos virus-like particle (VLP) platform to …

    Published on 1/12/2015
  • Daiichi Sankyo, Egalet deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Business: Neurology Egalet purchased Sprix ketorolac tromethamine nasal spray from Daiichi Sankyos Luitpold Pharmaceuticals Inc. …

    Published on 1/12/2015
  • ex scientia, Sumitomo Dainippon deal

    ex scientia Ltd., Dundee, U.K. Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Business: Neurology Sumitomo Dainippons Sunovion Pharmaceuticals Inc. subsidiary partnered with ex scientia to discover and …

    Published on 1/12/2015
  • GenSight Biologics, Pixium Vision, Fondation Voir et Entendre deal

    GenSight Biologics Inc., Paris, France Pixium Vision S.A. (Euronext:PIX), Paris, France Fondation Voir et Entendre, Paris, France Business: Ophthalmic GenSight, Pixium and public research organization Fondation Voir et …

    Published on 1/12/2015
  • Intellia Therapeutics, Novartis deal

    Intellia Therapeutics LLC, Cambridge, Mass. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Gene/Cell therapy Novartis received exclusive rights to Intellias gene-editing platform for ex vivo engineering …

    Published on 1/12/2015
  • Isis Pharmaceuticals, J&J deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Isis and Johnson & Johnsons Janssen Biotech Inc. unit partnered to discover and develop …

    Published on 1/12/2015
  • Kite Pharma, Amgen deal

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Business: Cancer Amgen will use Kites engineered autologous cell therapy (eACT) platform to develop chimeric antigen …

    Published on 1/12/2015
  • Merck, Kyorin deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Business: Autoimmune Mercks MSD K.K. subsidiary granted Kyorin co-marketing and co-promotion rights in …

    Published on 1/12/2015
  • Oncodesign, Isarna Therapeutics deal

    Oncodesign S.A. (Euronext:ALONC), Dijon, France Isarna Therapeutics GmbH, Munich, Germany Business: Cancer, Ophthalmic Oncodesign and Isarna extended through 2015 a February 2013 deal under which Oncodesign is …

    Published on 1/12/2015
  • Open Monoclonal Technology, HanAll deal

    Open Monoclonal Technology Inc., Palo Alto, Calif. HanAll Biopharma Co. Ltd. (KOSDAQ:009420), Seoul, South Korea Business: Antibodies OMT granted HanAll a license to use OmniRat, OmniMouse and OmniFlic platforms to …

    Published on 1/12/2015
  • Phenex, Gilead deal

    Phenex Pharmaceuticals AG, Ludwigshafen, Germany Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Business: Hepatic Gilead acquired Phenexs farnesoid X receptor (FXR; NR1H4) program for an undisclosed upfront …

    Published on 1/12/2015
  • Thermo Fisher, Samsung Electronics deal

    Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Samsung Electronics Co. Ltd. (LSE:SMSN;KSE:005930), Suwon, South Korea Business: Diagnostic Thermo Fisher and Samsung Electronics partnered to jointly develop and…

    Published on 1/12/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993